Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Deferred Taxes (2021 - 2024)

Prime Medicine filings provide 4 years of Deferred Taxes readings, the most recent being -$134000.0 for Q2 2024.

  • On a quarterly basis, Deferred Taxes fell 532.26% to -$134000.0 in Q2 2024 year-over-year; TTM through Mar 2025 was -$134000.0, a 335.09% decrease, with the full-year FY2023 number at -$279000.0, up 71.06% from a year prior.
  • Deferred Taxes hit -$134000.0 in Q2 2024 for Prime Medicine, down from $134000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $1.2 million in Q4 2021 to a low of -$532000.0 in Q1 2022.
  • Median Deferred Taxes over the past 4 years was -$121000.0 (2023), compared with a mean of $0.0.
  • The widest YoY moves for Deferred Taxes: up 166.34% in 2024, down 532.26% in 2024.
  • Prime Medicine's Deferred Taxes stood at $1.2 million in 2021, then plummeted by 116.25% to -$202000.0 in 2022, then surged by 46.53% to -$108000.0 in 2023, then dropped by 24.07% to -$134000.0 in 2024.
  • The last three reported values for Deferred Taxes were -$134000.0 (Q2 2024), $134000.0 (Q1 2024), and -$108000.0 (Q3 2023) per Business Quant data.